Logo

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

Share this
Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

Shots:  

  • The OLE P-II study involves assessing of Aimovig monthly (70mg) vs PBO in 383 eligible adult patients with an episodic migraine for 12wks. 250 patients increasing their dosage to 140mg monthly after a protocol amendment to assess the long-term safety of the higher dose
  • The results of the OLE study showed the therapy helped patients to achieve 5.3days reductions in MMD and 4.4 days reduction in the use of AMSM- and has the longest duration of safety and efficacy trial data for any anti-CGRP pathway therapy- will be presented at the Migraine Trust Virtual Symposium
  • Amgen will also present additional studies that include interim results of the LIBERTY OLE study- as well as efficacy and safety results of Aimovig in the EMPOwER study. Aimovig is the first and only FDA and EMA-approved migraine preventive treatment targeting CGRP receptor

­ Ref: Amgen | Image: CNBC

Related News: Amgen’s Aimovig (erenumab-aooe) Receives FDA’s Approval for Prevention of Migraine in Adults

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions